Detection of ISUP ≥2 prostate cancers using multiparametric MRI: prospective multicentre assessment of the non-inferiority of an artificial intelligence system as compared to the PI-RADS V.2.1 score (CHANGE study) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue BMJ Open Année : 2022

Detection of ISUP ≥2 prostate cancers using multiparametric MRI: prospective multicentre assessment of the non-inferiority of an artificial intelligence system as compared to the PI-RADS V.2.1 score (CHANGE study)

Olivier Rouvière
Rémi Souchon
  • Fonction : Auteur
Carole Lartizien
  • Fonction : Auteur
Adeline Mansuy
  • Fonction : Auteur
Laurent Magaud
  • Fonction : Auteur
Matthieu Colom
  • Fonction : Auteur
Marine Dubreuil-Chambardel
  • Fonction : Auteur
Sabine Debeer
  • Fonction : Auteur
Tristan Jaouen
  • Fonction : Auteur
Audrey Duran
  • Fonction : Auteur
Pascal Rippert
  • Fonction : Auteur
Benjamin Riche
  • Fonction : Auteur
Caterina Monini
Virginie Vlaeminck-Guillem
  • Fonction : Auteur
Julie Haesebaert
Sébastien Crouzet

Résumé

Introduction Prostate multiparametric MRI (mpMRI) has shown good sensitivity in detecting cancers with an International Society of Urological Pathology (ISUP) grade of ≥2. However, it lacks specificity, and its inter-reader reproducibility remains moderate. Biomarkers, such as the Prostate Health Index (PHI), may help select patients for prostate biopsy. Computer-aided diagnosis/detection (CAD) systems may also improve mpMRI interpretation. Different prototypes of CAD systems are currently developed under the Recherche Hospitalo-Universitaire en Santé / Personalized Focused Ultrasound Surgery of Localized Prostate Cancer (RHU PERFUSE) research programme, tackling challenging issues such as robustness across imaging protocols and magnetic resonance (MR) vendors, and ability to characterise cancer aggressiveness. The study primary objective is to evaluate the non-inferiority of the area under the receiver operating characteristic curve of the final CAD system as compared with the Prostate Imaging-Reporting and Data System V.2.1 (PI-RADS V.2.1) in predicting the presence of ISUP ≥2 prostate cancer in patients undergoing prostate biopsy. Methods This prospective, multicentre, non-inferiority trial will include 420 men with suspected prostate cancer, a prostate-specific antigen level of ≤30 ng/mL and a clinical stage ≤T2 c. Included men will undergo prostate mpMRI that will be interpreted using the PI-RADS V.2.1 score. Then, they will undergo systematic and targeted biopsy. PHI will be assessed before biopsy. At the end of patient inclusion, MR images will be assessed by the final version of the CAD system developed under the RHU PERFUSE programme. Key secondary outcomes include the prediction of ISUP grade ≥2 prostate cancer during a 3-year follow-up, and the number of biopsy procedures saved and ISUP grade ≥2 cancers missed by several diagnostic pathways combining PHI and MRI findings. Ethics and dissemination Ethical approval was obtained from the Comité de Protection des Personnes Nord Ouest III (ID-RCB: 2020-A02785-34). After publication of the results, access to MR images will be possible for testing other CAD systems. Trial registration number NCT04732156 .

Dates et versions

hal-04176579 , version 1 (03-08-2023)

Identifiants

Citer

Olivier Rouvière, Rémi Souchon, Carole Lartizien, Adeline Mansuy, Laurent Magaud, et al.. Detection of ISUP ≥2 prostate cancers using multiparametric MRI: prospective multicentre assessment of the non-inferiority of an artificial intelligence system as compared to the PI-RADS V.2.1 score (CHANGE study). BMJ Open, 2022, 12 (2), pp.e051274. ⟨10.1136/bmjopen-2021-051274⟩. ⟨hal-04176579⟩

Collections

HCL ANR
17 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More